HER3 and mutant EGFR meet MET

Research output: Contribution to journalShort surveypeer-review

65 Scopus citations


Non-small-cell lung cancers with activating mutations in the epidermal growth factor receptor develop resistance to tyrosine kinase inhibitors by recruiting the MET receptor kinase to activate HER3 and the PI3K-Akt cell survival pathway.

Original languageEnglish (US)
Pages (from-to)675-677
Number of pages3
JournalNature medicine
Issue number6
StatePublished - Jun 2007

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'HER3 and mutant EGFR meet MET'. Together they form a unique fingerprint.

Cite this